All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
Multiple Myeloma Hub Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, provided the Multiple Myeloma Hub with updates from this year's virtual American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Annual Congress. We asked, CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
CAR T-cell therapy or bispecific T-cell engagers for the treatment of patients with MM?
Significant improvements in both the diagnosis and treatment of MM have been observed in recent years. Despite this, MM remains an incurable disease and patients eventually relapse or become refractory to treatment. CAR T-cell therapy and bispecific T-cell engager monoclonal antibodies have demonstrated promising results in this setting. Here, María-Victoria Mateos outlines the major factors for consideration when choosing a patient's treatment course with such agents.
My experience with novel immunotherapies
During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, University of Würzburg, Würzburg,...
Editorial theme | How multiple myeloma cells develop resistance to/escape from BCMA-directed novel agents
This article is the first in the series of our newest editorial theme of mechanisms of escape/resistance to new therapies in multiple myeloma...
Subscribe to get the best content related to multiple myeloma delivered to your inbox